Clinical Trial Update: Annexin A2 as a Novel Diagnostic Marker in Hepatocellular Carcinoma

View source ↗

Summary

This completed clinical trial investigated Annexin A2 as a diagnostic biomarker for hepatocellular carcinoma, sponsored by Ain Shams University.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Snippet

Sponsor: Ain Shams University | Conditions: Hepatocellular Carcinoma (HCC) | Status: COMPLETED